Literature DB >> 22310863

Heart rate variability and metabolic syndrome in hospitalized patients with schizophrenia.

Kyunghee Lee1, Jeongeon Park, Jeongim Choi, Chang Gi Park.   

Abstract

PURPOSE: Reduced heart rate variability significantly increases cardiovascular mortality. Metabolic syndrome increases the cardiac autonomic dysfunction. Recently, increasing cardiovascular mortality has been reported in patients with schizophrenia. This study was done to compare heart rate variability between adults with and without schizophrenia and to compare the relationship of heart rate variability to metabolic syndrome in hospitalized patients with schizophrenia.
METHODS: This was a descriptive and correlational study in which 719 adults without schizophrenia and 308 adults with schizophrenia took part between May and June 2008. We measured the following: five-minute heart rate variability; high-frequency, low-frequency, the ratio of low-frequency to high-frequency, and the Standard Deviation of all the normal RR intervals. Data was also collected on metabolic syndrome, abdominal obesity, triglycerides, HDL cholesterol, blood pressure and fasting glucose.
RESULTS: The Standard Deviation of all the normal RR intervals values of heart rate variability indices were 1.53±0.18. The low-frequency and high-frequency values of heart rate variability indices were significantly higher in hospitalized patients with schizophrenia (3.89±1.36; 3.80±1.20) than those in the healthy participants (2.20±0.46; 2.10±0.46). There were no significant differences between the schizophrenic patients with and without metabolic syndrome.
CONCLUSION: The results of this study indicate that schizophrenia patients have significantly lower cardiac autonomic control, but they have significantly higher low-frequency and high-frequency values than those of healthy adults. Use of antipsychotic drug may affect the autonomic nervous system in schizophrenic patients. Metabolic syndrome was not associated with cardiac autonomic control in schizophrenia patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22310863     DOI: 10.4040/jkan.2011.41.6.788

Source DB:  PubMed          Journal:  J Korean Acad Nurs        ISSN: 2005-3673            Impact factor:   0.984


  7 in total

1.  The association and interaction analysis of metabolic syndrome and chronic kidney disease on cardiovascular autonomic neuropathy in the general Chinese population.

Authors:  Jin Zhang; Nai-Jia Liu; Yan Zhang; Hong Yang; Zachary Tang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Associations between the severity of metabolic syndrome and cardiovascular autonomic function in a Chinese population.

Authors:  Z Li; Z H Tang; F Zeng; L Zhou
Journal:  J Endocrinol Invest       Date:  2013-06-17       Impact factor: 4.256

Review 3.  Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders.

Authors:  Elizabeth K Nousen; Juliana G Franco; Elinor L Sullivan
Journal:  Neuroendocrinology       Date:  2013-09-21       Impact factor: 4.914

4.  Evaluation of autonomic nervous system by salivary alpha-amylase level and heart rate variability in patients with schizophrenia.

Authors:  Masa Ieda; Tsuyoshi Miyaoka; Rei Wake; Kristian Liaury; Keiko Tsuchie; Michiyo Fukushima; Tomoko Araki; Satoko Ezoe; Takuji Inagaki; Jun Horiguchi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-05-05       Impact factor: 5.270

Review 5.  Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health.

Authors:  Margaret K Hahn; Sri Mahavir Agarwal; Nicolette Stogios; Alexander Gdanski; Philip Gerretsen; Araba F Chintoh; Ariel Graff-Guerrero; Tarek K Rajji; Gary Remington
Journal:  NPJ Schizophr       Date:  2021-04-26

Review 6.  Metabolic syndrome in schizophrenia.

Authors:  Nidhi Malhotra; Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-07

7.  Impact of metabolic syndrome and its components on heart rate variability during hemodialysis: a cross-sectional study.

Authors:  Yu-Ming Chang; Chih-Chung Shiao; Ya-Ting Huang; I-Ling Chen; Chuan-Lan Yang; Show-Chin Leu; Hung-Li Su; Jsun-Liang Kao; Shih-Ching Tsai; Rong-Na Jhen; Ching-Cherng Uen
Journal:  Cardiovasc Diabetol       Date:  2016-01-27       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.